BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21876459)

  • 21. Nestin expression in cutaneous melanomas and melanocytic nevi.
    Brychtova S; Fiuraskova M; Hlobilková A; Brychta T; Hirnak J
    J Cutan Pathol; 2007 May; 34(5):370-5. PubMed ID: 17448190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Proof of a Clinical Concept: Expression of Estrogen Alpha-, Beta-Receptors and G Protein-Coupled Estrogen Receptor 1 (GPER) in Histologically Assessed Common Nevi, Dysplastic Nevi and Melanomas.
    Spałkowska M; Dyduch G; Broniatowska E; Damiani G; Wojas-Pelc A
    Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833446
    [No Abstract]   [Full Text] [Related]  

  • 23. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression.
    Tellez CS; Davis DW; Prieto VG; Gershenwald JE; Johnson MM; McCarty MF; Bar-Eli M
    J Invest Dermatol; 2007 Feb; 127(2):387-93. PubMed ID: 16946713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mast cells in melanocytic skin lesions. An immunohistochemical and quantitative study.
    Dyduch G; Okoń K; Pescarini E
    Pol J Pathol; 2011 Sep; 62(3):139-44. PubMed ID: 22102069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A distinctive melanocytic lesion associated with melanoma-prone dysplastic naevus syndrome: the hybrid naevus.
    Schubert C; Parwaresch R; Rudolph P
    Virchows Arch; 2001 Feb; 438(2):166-72. PubMed ID: 11253119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma.
    Giehl KA; Nägele U; Volkenandt M; Berking C
    J Cutan Pathol; 2007 Jan; 34(1):7-14. PubMed ID: 17214848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin.
    Giatromanolaki A; Sivridis E; Kouskoukis C; Gatter KC; Harris AL; Koukourakis MI
    Melanoma Res; 2003 Oct; 13(5):493-501. PubMed ID: 14512791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melanomas and Dysplastic Nevi Differ in Epidermal CD1c+ Dendritic Cell Count.
    Dyduch G; Tyrak KE; Glajcar A; Szpor J; Ulatowska-Białas M; Okoń K
    Biomed Res Int; 2017; 2017():6803756. PubMed ID: 28331853
    [No Abstract]   [Full Text] [Related]  

  • 29. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumor thickness.
    Sagebiel RW
    J Invest Dermatol; 1993 Mar; 100(3):322S-325S. PubMed ID: 8440914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi.
    Touab M; Arumi-Uría M; Barranco C; Bassols A
    Am J Clin Pathol; 2003 Apr; 119(4):587-93. PubMed ID: 12710131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
    Kiszner G; Wichmann B; Nemeth IB; Varga E; Meggyeshazi N; Teleki I; Balla P; Maros ME; Penksza K; Krenacs T
    Virchows Arch; 2014 May; 464(5):603-12. PubMed ID: 24682564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of cytoplasmic p27 expression in human melanoma.
    Chen G; Cheng Y; Zhang Z; Martinka M; Li G
    Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma.
    Chua R; Setzer S; Govindarajan B; Sexton D; Cohen C; Arbiser JL
    J Am Acad Dermatol; 2009 May; 60(5):758-66. PubMed ID: 19389518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions.
    Khare VK; Albino AP; Reed JA
    J Cutan Pathol; 1998 Jan; 25(1):2-10. PubMed ID: 9508337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms.
    Cohn ML; Goncharuk VN; Diwan AH; Zhang PS; Shen SS; Prieto VG
    J Cutan Pathol; 2005 Sep; 32(8):533-6. PubMed ID: 16115050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD44 and variants in melanocytic skin neoplasms.
    Schaider H; Soyer HP; Heider KH; Hofmann-Wellenhof R; Zatloukal K; Smolle J; Kerl H
    J Cutan Pathol; 1998 Apr; 25(4):199-203. PubMed ID: 9609138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
    Montone KT; van Belle P; Elenitsas R; Elder DE
    Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
    Fullen DR; Zhu W; Thomas D; Su LD
    J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nucleolin protein expression in cutaneous melanocytic lesions.
    Mourmouras V; Cevenini G; Cosci E; Epistolato MC; Biagioli M; Barbagli L; Luzi P; Mannucci S; Miracco C
    J Cutan Pathol; 2009 Jun; 36(6):637-46. PubMed ID: 19515042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.